The Technology
Pro-inflammatory cytokines in tumor microenvironment are known for their ability to either inhibit or promote cancer progression. Interleukin-31 (IL31), a protein belonging to the pro-inflammatory IL-6 cytokine family, inhibits tumor growth, reduces angiogenesis and metastases spread. Using chimeric IL-31 proteins fused to the FC fragment of IgG (IL-31-IgG) generates a stable IL-31 protein, that inhibits tumor growth, reduces angiogenesis and metastases spread. IL-31 can thus serve as a multi-targeted agent that affects both tumor and host-derived pro-tumorigenic cells.
Advantages
- Novel, multi-targeted agent that affects both tumor and host-derived pro-tumorigenic cells
Applications and Opportunities
- Novel cancer treatment affecting both tumor and pro-tumorigenic cells
- Synergistic additive treatment to existing cancer therapies
Business Development Contacts